Literature DB >> 20890742

The German S3 guideline prostate cancer: aspects for the radiation oncologist.

Frederik Wenz1, Thomas Martin, Dirk Böhmer, Stefan Martens, Felix Sedlmayer, Manfred Wirth, Kurt Miller, Axel Heidenreich, Mark Schrader, Wolfgang Hinkelbein, Thomas Wiegel.   

Abstract

This report summarizes the relevant aspects of the S3 guideline prostate cancer for the radiation oncologist. Treatment decision and dose prescription are discussed, as well as technical performance of external beam radiotherapy and brachytherapy. The relevant literature is cited to allow an overview of the current recommendations.

Entities:  

Mesh：

Year:  2010        PMID： 20890742     DOI： 10.1007/s00066-010-2193-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


  38 in total

1.  [Radiation therapy for prostate cancer in the new S3 guideline. Part 1: localized and locally advanced prostate cancer].

Authors:  D Böhmer; F Wenz; T Martin; F Sedlmayr; W Hinkelbein; T Wiegel
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

2.  [Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy].

Authors:  T Martin; F Wenz; D Böhmer; F Sedlmayer; W Hinkelbein; T O Henkel; K Miller; T Wiegel
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

3.  The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer.

Authors:  A D'Amico; M Altschuler; R Whittington; G Kao; S B Malkowicz; A Wein
Journal:  Clin Perform Qual Health Care       Date:  1993 Oct-Dec

4.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

Authors:  Anthony L Zietman; Kyounghwa Bae; Jerry D Slater; William U Shipley; Jason A Efstathiou; John J Coen; David A Bush; Margie Lunt; Daphna Y Spiegel; Rafi Skowronski; B Rodney Jabola; Carl J Rossi
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

5.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

6.  Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience.

Authors:  John E Sylvester; John C Blasko; Peter D Grimm; Robert Meier; Judith A Malmgren
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-11-15       Impact factor: 7.038

7.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

8.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

9.  High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial.

Authors:  Peter J Hoskin; Kate Motohashi; Peter Bownes; Linda Bryant; Peter Ostler
Journal:  Radiother Oncol       Date:  2007-05-24       Impact factor: 6.280

10.  Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

Authors:  Patrick A Kupelian; Louis Potters; Deepak Khuntia; Jay P Ciezki; Chandana A Reddy; Alwyn M Reuther; Thomas P Carlson; Eric A Klein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-01-01       Impact factor: 7.038
View more
  10 in total

1.  Reduction of dosimetric impact of intrafractional prostate motion during helical tomotherapy.

Authors:  V Prokic; H Geinitz; P Kneschaurek
Journal:  Strahlenther Onkol       Date:  2012-02-16       Impact factor: 3.621

2.  Application of a hydrogel spacer for postoperative salvage radiotherapy of prostate cancer.

Authors:  Michael Pinkawa; Carolin Schubert; Nuria Escobar-Corral; Richard Holy; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2014-10-23       Impact factor: 3.621

3.  Radiotherapy for prevention and therapy of gynecomastia due to antiandrogen treatment in prostate cancer patients: a patterns-of-care study.

Authors:  Burkhard Neu; Verena Sautter; Felix Momm; Ute Melcher; Heinrich Seegenschmiedt; Oliver Micke; Marie-Luise Sautter-Bihl
Journal:  Strahlenther Onkol       Date:  2011-11-29       Impact factor: 3.621

4.  Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable results.

Authors:  Gunnar Lohm; Dirk Bottke; Basil Jamil; Kurt Miller; Konrad Neumann; Detlef Bartkowiak; Wolfgang Hinkelbein; Thomas Wiegel
Journal:  World J Urol       Date:  2012-03-30       Impact factor: 4.226

5.  Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice.

Authors:  Cédric M Panje; Alan Dal Pra; Thomas Zilli; Daniel R Zwahlen; Alexandros Papachristofilou; Fernanda G Herrera; Oscar Matzinger; Ludwig Plasswilm; Paul Martin Putora
Journal:  Strahlenther Onkol       Date:  2015-05-19       Impact factor: 3.621

6.  Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study.

Authors:  Alessandra Siegmann; Dirk Bottke; Julia Faehndrich; Gunnar Lohm; Kurt Miller; Detlef Bartkowiak; Thomas Wiegel; Wolfgang Hinkelbein
Journal:  Strahlenther Onkol       Date:  2011-07-22       Impact factor: 3.621

7.  Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy : Long-term follow-up of a single-center survey.

Authors:  Gunnar Lohm; Jörg Lütcke; Basil Jamil; Stefan Höcht; Konrad Neumann; Wolfgang Hinkelbein; Thomas Wiegel; Dirk Bottke
Journal:  Strahlenther Onkol       Date:  2014-02-28       Impact factor: 3.621

Review 8.  [The importance of pathology in the German prostate cancer study PREFERE].

Authors:  G Kristiansen; M Stöckle; P Albers; H Schmidberger; P Martus; S Wellek; M Härter; R Bussar-Maatz; T Wiegel
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

9.  A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients.

Authors:  Ulf W Tunn
Journal:  BMC Urol       Date:  2011-07-29       Impact factor: 2.264

10.  Re-implantation after insufficient primary 125-i permanent prostate brachytherapy.

Authors:  Paul Martin Putora; Ludwig Plasswilm; Wolf Seelentag; Johann Schiefer; Patrick Markart; Hans-Peter Schmid; Daniel Engeler
Journal:  Radiat Oncol       Date:  2013-08-06       Impact factor: 3.481
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.